NPI 1689172389: Open Payments
NPI 1689172389. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$133 in 7 payments from 5 companies in 2025. Trend: 2023 $497 · 2024 $834 · 2025 $133
Food & beverage: $133
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 2 | $39 |
| GlaxoSmithKline, LLC. | 2 | $28 |
| Phathom Pharmaceuticals, Inc. | 1 | $28 |
| PFIZER INC. | 1 | $21 |
| ABBVIE INC. | 1 | $18 |
Products named: TRELEGY ELLIPTA, VOQUEZNA, PAXLOVID, JARDIANCE, MOUNJARO, VRAYLAR.
